Collaborations
MPRINT collaborates with institutions around the globe in cutting-edge research into maternal and pediatric pharmacology.
Here are just a few of our many partners in improving health outcomes during pregnancy and childhood.
The Human Milk Institute (HMI) at UC San Diego brings together researchers, clinicians, and educators to advance the science of human milk and lactation. Through research, education, and collaboration, HMI works to improve maternal and child health and translate discoveries into clinical practice and public health.
MFMU incorporates translational research, genetic analysis, and the evaluation of new technologies in the promotion of maternal-child health/prevention of disease.
Integrated Transporter Elucidation Center (InTEC) is an NIH-funded research center that studies placental transporters and their role in moving medications, nutrients, and other compounds between mother and fetus. Its goal is to improve medication safety and maternal and fetal health during pregnancy.
LIFE RAFT is a program designed to give families facing high-risk pregnancies the specialized breastfeeding support they need—before birth, in the hospital, and throughout the first year of their baby’s life.
The Pediatric Trials Network (PTN) is studying the formulation, dosing, efficacy, and safety of drugs, as well as the development of medical devices, used in pediatric patients.
IMPAACT aims to improve health outcomes in infancy, childhood, adolescence, pregnancy, and postpartum among those who are impacted by or living with HIV by evaluating novel treatments and interventions for HIV, tuberculosis, and other related complications.
LactMed® is a free, evidence-based database from the National Library of Medicine that provides information on medications and other substances used during breastfeeding, including drug levels in breast milk, potential effects on nursing infants, and safer alternatives when available.
TRRP
Project Description
The overarching goal of the project is to develop a novel platform using exosome profiling as biomarkers to monitor placental-mediated adverse pregnancy outcomes and response to therapeutics. Using preeclampsia as the model condition and aspirin as the therapeutic agent, the study will conduct a prospective observational
observational cohort study of people receiving aspirin for preeclampsia prevention to develop and validate extracellular vesicle proteome profiles of placental function, evaluate associations with aspirin exposure, and examine relationships with angiogenic biomarkers and clinical outcomes.
Project Team
-
Principal Investigator: Maged Costantine, MD, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University
-
Co-Principal Investigator: Ramkumar Menon, PhD, Professor, Department of Obstetrics and Gynecology and Director of the Basic Science and Translational Research Laboratory, The University of Texas Medical Branch
Co-Investigators
-
Kara Rood, MD, The Ohio State University
-
Brian Searle, PhD, Mayo Clinic
-
Damien Wilburn, PhD, The Ohio State University
-
Mitch Phelps, PhD, The Ohio State University
-
Ananth Kumar Kamala, PhD, The University of Texas Medical Branch
-
Melanie Paglione, RN, The Ohio State University
-
Taryn Summerfield, BS, MS, CCRP, The Ohio State University